Quick Answer
Choline Sleep Quality Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: 1 2 3–6 7 8 9 10–12 13 14 Hyperlipidemia (HLP) refers to a systemic lipid metabolism abnormality characterized by elevated levels of total cholesterol (TC), triglycerides (TG), and/or low-density lipoprotein cholesterol (LDL-C), and/or reduced levels of high-density lipoprotein cholesterol (HDL-C) in the plasma due to various causes.
Key Takeaways
- 011 2 3–6 7 8 9 10–12 13 14 Hyperlipidemia (HLP) refers to a systemic lipid metabolism abnormality characterized by elevated levels of total cholesterol (TC), triglycerides (TG), and/or low-density lipoprotein cholesterol (LDL-C), and/or reduced levels of high-density lipoprotein cholesterol (HDL-C) in the plasma due to various causes. [Xie Haihua (2026)]
- 02HLP, particularly elevated LDL-C levels, has been established as a risk factor for cardiovascular diseases and cognitive disorders (CD) [,]. [Xie Haihua (2026)]
- 03It has been reported that alterations in plasma lipid profiles appear to exacerbate cognitive decline, thereby increasing the risk of developing Alzheimer’s disease in non-demented elderly individuals []. [Xie Haihua (2026)]
- 04While intrinsic genetic factors drive much of this neurodevelopment, emerging evidence highlights the influence of extrinsic factors, particularly gut health, sleep architecture, and nutrition [,]. [Chaturvedi Devyani (2026)]
The current Migaku evidence database contains 2 reusable source documents for Choline Sleep Quality Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- 1 2 3–6 7 8 9 10–12 13 14 Hyperlipidemia (HLP) refers to a systemic lipid metabolism abnormality characterized by elevated levels of total cholesterol (TC), triglycerides (TG), and/or low-density lipoprotein cholesterol (LDL-C), and/or reduced levels of high-density lipoprotein cholesterol (HDL-C) in the plasma due to various causes. [Xie Haihua (2026); evidence level 2]
- HLP, particularly elevated LDL-C levels, has been established as a risk factor for cardiovascular diseases and cognitive disorders (CD) [,]. [Xie Haihua (2026); evidence level 2]
- It has been reported that alterations in plasma lipid profiles appear to exacerbate cognitive decline, thereby increasing the risk of developing Alzheimer’s disease in non-demented elderly individuals []. [Xie Haihua (2026); evidence level 2]
- While intrinsic genetic factors drive much of this neurodevelopment, emerging evidence highlights the influence of extrinsic factors, particularly gut health, sleep architecture, and nutrition [,]. [Chaturvedi Devyani (2026); evidence level 3]
- However, disruptions in this process may result from factors such as cesarean delivery, antibiotic exposure, early-life stress, or diets lacking key nutrients and probiotics that favorably modulate the gut microbiota, thereby directly impacting neurodevelopmental outcomes. [Chaturvedi Devyani (2026); evidence level 3]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources